Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function

Description

List of Tables

The Next-Generation Cancer Diagnostics Market was valued at USD 9.77 billion in 2023, expected to reach USD 12.02 billion in 2024, and is projected to grow at a CAGR of 24.12%, to USD 44.36 billion by 2030.

Next-generation cancer diagnostics refer to advanced technologies and methodologies used to detect cancer at an early stage and monitor its progression with high precision. These diagnostics encompass a range of innovations such as liquid biopsies, next-generation sequencing (NGS), and advanced imaging techniques, which improve the accuracy and timeliness of cancer detection. The necessity of such cutting-edge diagnostics lies in their ability to improve patient outcomes by enabling early diagnosis, personalized treatment plans, and real-time monitoring of treatment efficacy. Applications span across hospitals, diagnostic labs, research institutes, and directly to patients through personalized health solutions. These technologies are predominantly used in the detection of prevalent cancers such as breast, lung, and colorectal cancers and are increasingly applied in precision medicine and personalized oncology.

KEY MARKET STATISTICS
Base Year [2023]	USD 9.77 billion
Estimated Year [2024]	USD 12.02 billion
Forecast Year [2030]	USD 44.36 billion
CAGR (%)	24.12%

Key growth factors in this market include the rising prevalence of cancer, increasing awareness about early detection, and the shift towards personalized medicine. Moreover, technological advancements, government investments, and favorable regulatory policies are propelling growth. Emerging opportunities include developing non-invasive diagnostic tools, leveraging artificial intelligence for predictive diagnostics, and expanding access in emerging markets. However, challenges persist including high costs of advanced technologies, stringent regulatory hurdles, and the complexity of integrating new tools into existing healthcare infrastructure. Additionally, varied reimbursement landscapes can hinder market growth.

The best areas for innovation lie in improving the cost-effectiveness of diagnostic tools, enhancing data integration and management for better patient outcomes, and expanding biomarker discovery. As the market has a dynamic and competitive nature, with numerous startups and established players exploring innovative paths, staying ahead by focusing on R&D and strategic partnerships can provide a competitive edge. Companies should prioritize addressing affordability and accessibility challenges by developing scalable and easy-to-use diagnostic solutions to expand their reach and impact on cancer management globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Cancer Diagnostics Market

The Next-Generation Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
- Growing Utilization of Microfluidic Chips in Cancer Management
- Government Initiatives Towards Cancer Screening
Market Restraints
- High Investment and Insufficient Standardization of Diagnostics
Market Opportunities
- Proliferation of Personalized and Advanced Genome Medicine
- Technological Advancements in Next-Generation Cancer Diagnostics
Market Challenges
- Limitations and Risks Associated with NGC Diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Cancer Diagnostics Market

A detailed market share analysis in the Next-Generation Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Thermo Fisher Scientific, Inc., bioMerieux SA, Akadeum Life Sciences, Hologic Inc., NeoGenomics Laboratories, Biological Dynamics Inc., Bio-Techne Corporation, Johnson & Johnson Services, Inc., Oxford Nanopore Technologies Limited, Novartis AG, Exact Sciences Corporation, Castle Biosciences Inc., Qiagen N.V., Agilent Technologies, Inc., Perkin Elmer, Inc., Sysmex Corporation, Becton, Dickinson & Company, GE HealthCare, Danaher Corporation, Almac Group, BioNTech SE, Telerad Tech, Konica Minolta, Inc., Agena Bioscience, Inc. by Mesa Laboratories, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Adaptive Biotechnologies Corporation, Abbott Laboratories, Siemens Healthineers AG, OPKO Health, Inc., and Koninklijke Philips N.V..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics, DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
Based on Cancer Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer, and Uterine Cancer.
Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Prognostics, Risk Analysis, and Therapeutic Monitoring.
Based on Function, market is studied across Biomarker Development, CTC Analysis, Epigenetic Analysis, Genetic Analysis, and Proteomic Analysis.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-AD36CD898567

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
  - 5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
  - 5.1.1.3. Government Initiatives Towards Cancer Screening
- 5.1.2. Restraints
  - 5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
- 5.1.3. Opportunities
  - 5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
  - 5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
- 5.1.4. Challenges
  - 5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
- 5.2.2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
5.5. Client Customization

6. Next-Generation Cancer Diagnostics Market, by Technology

6.1. Introduction
6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
6.3. DNA Microarrays
6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
6.5. Molecular Diagnostics
6.6. Next Generation Sequencing
6.7. Protein Microarrays
6.8. qPCR & Multiplexing

7. Next-Generation Cancer Diagnostics Market, by Cancer Type

7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Lung Cancer
7.8. Pancreatic Cancer
7.9. Prostate Cancer
7.10. Thyroid Cancer
7.11. Uterine Cancer

8. Next-Generation Cancer Diagnostics Market, by Application

8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring

9. Next-Generation Cancer Diagnostics Market, by Function

9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis

10. Americas Next-Generation Cancer Diagnostics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Next-Generation Cancer Diagnostics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
- 13.3.2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
- 13.3.3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
- 13.3.4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
- 13.3.5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
- 13.3.6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

Companies Mentioned

1. Thermo Fisher Scientific, Inc.
2. bioMerieux SA
3. Akadeum Life Sciences
4. Hologic Inc.
5. NeoGenomics Laboratories
6. Biological Dynamics Inc.
7. Bio-Techne Corporation
8. Johnson & Johnson Services, Inc.
9. Oxford Nanopore Technologies Limited
10. Novartis AG
11. Exact Sciences Corporation
12. Castle Biosciences Inc.
13. Qiagen N.V.
14. Agilent Technologies, Inc.
15. Perkin Elmer, Inc.
16. Sysmex Corporation
17. Becton, Dickinson & Company
18. GE HealthCare
19. Danaher Corporation
20. Almac Group
21. BioNTech SE
22. Telerad Tech
23. Konica Minolta, Inc.
24. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
25. Illumina, Inc.
26. F. Hoffmann-La Roche Ltd.
27. Adaptive Biotechnologies Corporation
28. Abbott Laboratories
29. Siemens Healthineers AG
30. OPKO Health, Inc.
31. Koninklijke Philips N.V.